Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapolsertib + glofitamab
- Development stage
- Phase 2
- Lead developer
- Menarini
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
dapolsertib + glofitamab is a combination investigational therapy currently in clinical development for **relapsed/refractory aggressive B-cell non-Hodgkin lymphoma**. - **dapolsertib** (MEN1703, SEL24) is an orally bioavailable, small-molecule **dual inhibitor of PIM and FLT3 kinases**, implicated in malignant transformation and lymphomagenesis[5]. - **glofitamab** is a bispecific monoclonal antibody that binds **bivalently to CD20** on B cells and **monovalently to CD3** on T cells, bridging them to form an immunological synapse, resulting in T-cell activation, cytokine release, and lysis of CD20-expressing malignant B cells[2][4][8][10]. The combination is being evaluated primarily for B-cell non-Hodgkin lymphoma in phase II clinical trials[1][5], aiming to leverage dapolsertib's kinase inhibition together with the T-cell-mediated cytotoxicity promoted by glofitamab.
- Other names
- dapolsertib hydrochlorideglofitamab
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)FLT3 (Fms related receptor tyrosine kinase 3)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)PIM2 (Proto-oncogene serine/threonine-protein kinase Pim2)PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)
Beyond the preview
Go deeper on dapolsertib + glofitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapolsertib + glofitamab.